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Introduction {#sec001}
============

Although approximately 60--70% of human patients with osteosarcoma (OSA) treated with standard of care multimodality therapy experience long-term survival, these numbers have remained static for the past three decades, and the survival of patients with relapsed and/or metastatic OSA is dismal \[[@pone.0224775.ref001]--[@pone.0224775.ref003]\]. Despite evidence that OSA can be recognized by the immune system \[[@pone.0224775.ref004]--[@pone.0224775.ref006]\], the clinical experience with immunotherapy for OSA has been disappointing. Moreover, evaluating and optimizing immunotherapy for an orphan disease where up to 70% of patients experience long-term survival is challenging. Indeed, poor compliance and retention in this patient population has been reported in the recently completed worldwide EURAMOS trial \[[@pone.0224775.ref007]\], clearly demonstrating the challenges of evaluating immunotherapy in a disease with overall favorable, but variable outcomes.

Companion dog OSA demonstrates remarkable similarity to the complexity and heterogeneity of human OSA \[[@pone.0224775.ref008],[@pone.0224775.ref009]\]. Importantly, unlike murine models of cancer based on tumor injections and/or genetic-engineering, dogs develop spontaneous cancers in the setting of an intact immune system, and naturally-occurring cancers in dogs recapitulate the important host/tumor principles of immune equilibrium, immune evasion, and immune escape \[[@pone.0224775.ref008],[@pone.0224775.ref010],[@pone.0224775.ref011]\]. In addition, the burden of dog cancer, including OSA, is significant, and some investigators have estimated that the prevalence of cancer in companion dogs is higher than that of humans \[[@pone.0224775.ref008]\]. Since there is a less established standard of care in veterinary medicine, investigational treatments, such as immunotherapy, can be considered earlier in the course of therapy, thereby allowing for testing of novel therapies that can speed translation of innovative therapies to both dogs and humans \[[@pone.0224775.ref011]\]. Taken together, dogs with naturally occurring cancer represent an ideal model to evaluate novel immunotherapy approaches. Trials in companion animals are an important bridge between pre-clinical testing in murine models and clinical trials in people and allow for important proof-in-concept studies of innovative new strategies. Concurrently, dog clinical trials provide key preliminary data on efficacy and toxicity in a large animal model with notable similarity to people \[[@pone.0224775.ref011]\]. However, canine trials remain nascent, and more studies are needed to underscore the generalizability of the findings, the similarities of the immune readouts, and the validation of key reagents.

Given our preliminary data showing that radiotherapy (RT) sensitizes tumors, including sarcomas, to NK cytotoxicity as well as the unmet need for effective immunotherapy in OSA \[[@pone.0224775.ref012]\], we previously conducted a clinical trial in dogs of palliative RT plus intra-tumoral autologous NK transfer in dogs with non-metastatic OSA whose owners elected not to pursue amputation or cytotoxic chemotherapy \[[@pone.0224775.ref013]\]. As part of this clinical trial, we collected serial blood and tumor specimens pre- and post-treatment to assess serum cytokines, to evaluate immune phenotype of circulating PBMCs, and to analyze gene expression in tumor tissue. Our objective was to analyze blood and tissue specimens as correlates of clinical response to NK/RT immunotherapy, and we hypothesized that analysis of blood and tumor tissue would further validate the dog model for canine immunotherapy studies and would provide preliminary evidence of local or systemic immune response to treatment for testing in a larger trial. As our clinical trial enrollment in dogs was small, we also queried The Cancer Genome Atlas (TCGA) to analyze the association of intra-tumoral immune gene expression with survival in human sarcomas to further inform the relevance of dog sarcomas in the evaluation of novel immunotherapy approaches on the path to human clinical testing.

Materials and methods {#sec002}
=====================

First-in-Dog clinical trial {#sec003}
---------------------------

The schema of the enrollment, NK isolation and expansion, and radio-immunotherapy protocol have been described previously \[[@pone.0224775.ref013]\]. In brief, dogs were considered eligible if they were diagnosed with locally advanced, non-metastatic OSA, had adequate end organ function, and were not pursuing amputation or chemotherapy. Our study enrollment was designed to accrue 10 patients in order to evaluate the primary endpoint of lung metastasis formation at 6 months. The clinical trial was approved by the UC Davis School of Veterinary Medicine Clinical Trials Review Board and the Institutional Animal Care and Use Committee (protocol \#18857).

The clinical protocol consisted of 4 fractions of palliative RT at a dose of 9 Gy weekly followed by two intra-tumoral injections of *ex vivo* expanded autologous canine NK cells (7.5 x 10^6^ NK cells/kg) in 1--2 mL aliquots in sterile PBS during weeks 5 and 6 \[[@pone.0224775.ref013]\]. Ex vivo expanded canine NK cells are obtained similar to the method previously described \[[@pone.0224775.ref014],[@pone.0224775.ref015]\], utilizing co-culture of canine peripheral blood with irradiated human erythroleukemia K562 cell line engineered to express membrane bound IL-21 and 4-1bb ligand, supplemented with 100 IU/mL rhIL-2. Recombinant human IL-2 was co-injected with the NK cells at a dose of 250,000 IU/kg (Roche, NCI, Frederick). Resting dog NK cells were isolated from a CD5^dim^ population \[[@pone.0224775.ref016]\], but when activated and mature were phenotyped as CD5-/CD3-/NKp46+ \[[@pone.0224775.ref017]\]. We assessed for lung metastasis using thoracic computed tomography every three months for the first six months of follow-up followed by thoracic radiographs every three months thereafter.

Serum cytokine measurement {#sec004}
--------------------------

Pre-treatment serum cytokine levels were measured as a baseline using serum isolated from canine peripheral blood by centrifugation. Serum concentrations of IL-2, IL-6, and TNFα were measured using dog-specific ELISA plates per manufacturer's specifications (Kingfisher Biotech, MN, USA). Pre-treatment values were retrospectively correlated with survival.

qRT-PCR {#sec005}
-------

Total RNA was extracted from PBMCs and CD5-depleted cells using the RNeasy Mini Kit (Qiagen) and from tumor biopsies and normal lymph node using the RNeasy Fibrous Tissue Mini Kit (Qiagen). Tumor samples were first stored in RNAlater solution (Invitrogen) before being homogenized using a TissueLyser II system (Qiagen). Extracted RNA was reverse transcribed to cDNA using iScript Reverse Transcription Supermix (Bio-Rad). Gene-specific primers were obtained from Bio-Rad and Integrated DNA Technologies; additional primer information can be found in [S1 Table](#pone.0224775.s001){ref-type="supplementary-material"}. Quantitative real-time PCR was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) and the StepOnePlus Real-Time PCR system (Applied Biosystems). Briefly, reactions containing 5 ng of cDNA were subjected to the thermal cycling conditions recommended by the SsoAdvanced manual for use with the StepOnePlus system: initial 30 seconds at 95 degrees Celsius followed by 40 cycles of denaturation for 15 seconds at 95 degrees Celsius and annealing and extension for 60 seconds at 60 degrees Celsius.

Flow cytometry {#sec006}
--------------

5 × 105--106 cells were stained in round bottom 96 well plates. Surface antibodies were diluted with staining buffer (2% FBS, 1 mM EDTA, and 0.02% NaN3 in PBS) and blocking buffer using canine Fc receptor binding inhibitor (ThermoFisher, \#14--9162--42) and canine gamma globulin (Jackson ImmunoResearch, \#004--000--002). Details regarding specific antibodies utilized in this study can be found in [S2 Table](#pone.0224775.s002){ref-type="supplementary-material"}. For intracellular staining of canine interferon-γ and granzyme B, cells were mixed with viability stain, then washed and incubated with fixation and permeabilization solution per manufacturer's instructions (BD Biosciences). We then incubated with intracellular stain or isotype prepared in Perm/Wash Buffer^™^ followed by centrifugation and resuspension in 1% paraformaldehyde for flow cytometry analysis. Fluorescent minus one (FMO) controls containing all the fluorochromes in the panel except the one for that marker of interest were used to control for fluorescent spread due to multiple fluorochromes in a given panel.

Cytotoxicity assays {#sec007}
-------------------

NK cytotoxicity was determined by flow cytometry using co-culture assays with expanded NK cells and the prototypical dog NK target line, canine thyroid adenocarcinoma cells (CTAC) \[[@pone.0224775.ref013],[@pone.0224775.ref016]\]. SSC^hi^ CD45-7AAD− and SSChi CD45-7AAD+ populations were analyzed relative to control tumor cells not exposed to NK co-culture. All data were collected using a BD Fortessa flow cytometer equipped with BD FACSDiva software (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo software (TreeStar, Ashland, OR). The characteristics of our purified mouse anti-canine NKp46 antibody have been described previously \[[@pone.0224775.ref017]\].

Animal studies {#sec008}
--------------

As noted above, the clinical trial portion of this study was approved by the UC Davis School of Veterinary Medicine Clinical Trials Review Board and IACUC (protocol \#18857) and consisted of 10 dogs with naturally occurring, spontaneous OSA. Additional client-owned dogs with OSA (N = 2) or soft tissue sarcoma (N = 3) underwent surgery at the UC Davis Health Veterinary Medical Teaching Hospital (VMTH), and tumor tissue was obtained with owner consent (protocol \#18315) for immunohistochemistry and immune analysis. Lymph node tissue was obtained from a dog undergoing necropsy, also with owner consent (protocol \#20416). Blood was also obtained from farm-bred beagles (N = 6) per commercial relationship (Ridglan Farms, Inc., Mt. Horeb, WI) using EDTA tubes diluted with sterile PBS. Per Ridglan literature, their beagle colony is maintained using the strictest standards of quality in breeding, socialization, and animal welfare.

The cancer genome atlas {#sec009}
-----------------------

Using the Data Matrix from TCGA website (<https://tcgadata.nci.nih.gov/tcga/dataAccessMatrix.htm>), we downloaded clinical and genomic data from the TCGA provisional soft tissue sarcoma (STS) data set on May 30, 2018 using the TCGA data portal (<https://portal.gdc.cancer.gov/>). Gene expression data for CD3e, CD8a, IFNG, GZMB, PRF1, CD122, IL-6, and IL-6R (CD126) were downloaded from the Computational Biology Center at Memorial Sloan-Kettering cBioPortal website (<http://www.cbioportal.org/>). Using TCGA barcodes, we matched the TCGA clinical and genomic data for individual patients. We compared overall survival (OS) for high and low gene expression using the 1^st^ and 4^th^ quartiles of the TCGA genes of interest using the Kaplan-Meier method, the log-rank test, and Cox proportional hazards models.

Statistical considerations {#sec010}
--------------------------

Summary statistics were reported as mean ± standard error with median (range) where appropriate. Categorical variables were compared using a chi-squared test. Parametric continuous variables were compared using an independent samples t-test. Non-parametric continuous variables were compared using the Mann-Whitney U test. For comparison of more than two groups, statistical significance was determined using a one-way ANOVA followed by a Bonferroni multiple-group comparison test. Survival curves were created using the Kaplan-Meier method. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC) and Graph-Pad Prism 5. Significance was set at P \< 0.05.

Results {#sec011}
=======

First-in-dog trial of RT and NK cell immunotherapy {#sec012}
--------------------------------------------------

Clinical characteristics and vital status of the canine patients from the clinical trial are detailed in [Table 1](#pone.0224775.t001){ref-type="table"}. Among the 10 treated dogs, the mean age was 8.0 ± 3.3 years, and four were female (40%). The median body condition score was 6 (range 3--8), and the mean weight was 50 ± 21 kg. In all, the trial included three St. Bernards, three mixed breed dogs, and one each of the following: Labrador Retriever, Doberman pinscher, Pyrenees, and Rhodesian Ridgeback. The majority of OSA were located at the distal radius (60%), with other sites being the ilium (20%) and humerus (20%). With a median follow up of 5.7 months (9.7 months for survivors), six patients died for an overall mortality of 60%. Four dogs were euthanized secondary to progressive OSA, while 2 patients died from causes unrelated to cancer (1 from a perforated ulcer presumably from non-steroidal anti-inflammatory drugs and 1 from euthanasia after suffering a pathologic fracture post RT and local recurrence). The updated event-free overall and progression-free survival for the cohort are shown in [Fig 1](#pone.0224775.g001){ref-type="fig"}.

![Kaplan-Meier analysis of updated event-free and overall survival for ten dogs on trial.\
Kaplan-Meier survival curves for lung-metastasis free survival (dashed line) and overall survival (solid line) for dogs with locally advanced, non-metastatic osteosarcoma treated with palliative radiotherapy and intra-tumoral NK transfer x2. Median survival was not reached for lung-metastasis free survival during the follow up period.](pone.0224775.g001){#pone.0224775.g001}

10.1371/journal.pone.0224775.t001

###### Clinical characteristics and vital status of canine patients on clinical trial.

![](pone.0224775.t001){#pone.0224775.t001g}

  Characteristic                               Number (%)    
  -------------------------------------------- ------------- -----------
  Age, mean ± SD                                             8.0 ± 3.3
  Sex                                          Male          6 (60%)
  Female                                       4 (40%)       
  Body Condition Score median (range)                        6 (3--8)
  Weight, mean (kg) ± SD                                     50 ± 21
  Breed                                        St. Bernard   3 (30%)
  Shepherd Mix                                 2 (20%)       
  Other[\*](#t001fn001){ref-type="table-fn"}   5 (50%)       
  Tumor Location                               Radius        6 (60%)
  Ilium                                        2 (20%)       
  Humerus                                      2 (20%)       
  Vital Status                                 Alive         4 (40%)
  Dead                                         6 (60%)       

\* Includes Black Lab, Pyrenees, Doberman, Retriever Mix, and Rhodesian Ridgeback.

Ex Vivo NK cell expansion {#sec013}
-------------------------

PBMCs were isolated from trial subjects, and NK cells were isolated for activation and expansion using CD5 depletion to enrich for the CD5^dim^ subset. As shown in [Fig 2A](#pone.0224775.g002){ref-type="fig"}, pre-depletion PBMCs from trial subjects and healthy laboratory beagles are characterized by absent NKp46 expression and mixed CD3 expression, whereas the CD5 depleted population is enriched for NKp46+ cells which are CD3 negative. After two weeks in co-culture with an irradiated feeder line \[[@pone.0224775.ref018]\], the CD3-NKp46+ population markedly expands from 0.6 ± 0.5% in circulating PBMCs to 8.1 ± 2.7% at day 0 post CD5 depletion to 81.3 ± 13.9% at day 14 in co-culture (P \< 0.05 from N = 6 beagles). As shown in [Fig 2B](#pone.0224775.g002){ref-type="fig"}, there is concomitant upregulation of cytotoxic marker granzyme B after CD5 depleted cells are co-cultured in K562.clone9 cells for 14 days with 100 IU/mL rhIL-2.

![Canine NK cells are enriched in NKp46 and Granzyme B expression with time-dependent changes in cytotoxic function.\
(A) Canine NK cells were isolated from peripheral blood mononuclear cells via CD5 antibody depletion (left), thereby enriching for a CD3-NKp46+ population of cells (right). (B) Ex vivo expansion with an irradiated feeder cell line (human K562 leukemia line transduced with 4-1BBL and membrane bound IL-21) yields a CD3 population of cells that are markedly positive for NKp46+ (left) and Granzyme B+ (right) after 14 days of stimulation. For panels A and B, representative flow cytometry plots from 10 study dogs and 6 healthy beagles are shown. (C) The cytotoxicity of NK cells was assayed at multiple time points (using CTAC cells as targets) and compared to fresh PBMCs (incubated with 100 IU/mL rhIL-2) in 12--16 hour killing assays. Data from one experiment performed in triplicate are shown. Mean values ± SD are shown. This experiment was repeated with 3 different beagle donors. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001, \*\*\*\* P\<0.0001 via one-way ANOVA with Tukey's post-test.](pone.0224775.g002){#pone.0224775.g002}

We also assessed NK cytotoxic function in killing assays from selected time points using both trial subjects and laboratory beagles. As shown in [Fig 2C](#pone.0224775.g002){ref-type="fig"}, after 17--20 days in co-culture NK cells demonstrated maximal cytotoxicity to canine thyroid adenocarcinoma (CTAC) target cells although we observed no statistically significant differences in cytotoxic function between day 17--20 and day 14 NK cells (P \> 0.05) using blood from 3 beagles. However, by day 20--24 post expansion, we observed a diminution in NK cytotoxic function which was significantly less than day 14 and day 17--20 cells (although elevated above resting PBMCs, P \< 0.01).

Serum cytokines {#sec014}
---------------

[Fig 3](#pone.0224775.g003){ref-type="fig"} highlights the baseline/ pre-treatment serum cytokine levels between dogs who lived ≥ 6 months and dogs who died within 6 months of study entry. Mean canine serum IL-2 by ELISA ([Fig 3A](#pone.0224775.g003){ref-type="fig"}) was 99.4 ± 53.4 pg/ mL in 6-month survivors (our primary endpoint for the trial) compared to 162.9 ± 124.9 (P \> 0.05) in non-survivors. Mean canine serum TNF-α ([Fig 3C](#pone.0224775.g003){ref-type="fig"}) was 42.5 ± 60.1 pg/ mL in 6-month survivors compared to 44.9 ± 44.9 in non-survivors (P \> 0.05). As shown in [Fig 3B](#pone.0224775.g003){ref-type="fig"}, the difference in serum IL-6 between dogs who lived ≥ 6 months (0.0 ± 0 pg/ mL) and those who died within 6 months (32.1 ± 19.2 pg/ mL) was not significantly different (P = 0.08). Notably, however, of the four study subjects with undetectable serum IL-6 at baseline, three patients (75%) were alive at six months compared to four study subjects with detectable serum IL-6 who all died within 6 months of study entry. Two dogs could not be evaluated because of insufficient serum for analysis at the indicated time point.

![Baseline serum cytokine expression in trial patients.\
Baseline expression of serum cytokines was compared between dogs who were alive at 6 months versus those who died. There was no significant different in serum IL-2 (A) or serum TNF-α (C) between survivors and non-survivors. Baseline serum IL-6 (B) was notably higher in non- survivors (32.1 pg/mL ±19.2) compared to survivors (not detectable), although this difference was not statistically significant (P = 0.08).](pone.0224775.g003){#pone.0224775.g003}

Circulating immune phenotype {#sec015}
----------------------------

As shown in [Fig 4](#pone.0224775.g004){ref-type="fig"}, we also performed flow phenotyping of circulating immune populations from baseline PBMCs, analyzing the percentage of circulating CD45+ cells for granzyme B and IFN-γ expression at study entry. We have shown previously that granzyme B expression by circulating CD45+ cells is significantly increased in paired patient blood samples after intra-tumoral NK transfer \[[@pone.0224775.ref013]\]. However, in the current analysis, when looking at baseline circulating immune phenotype (within 7 days of initiation of palliative RT), we observed no significant difference (P \> 0.05) in percent positive circulating granzyme B+/CD45+ cells ([Fig 4A--4C](#pone.0224775.g004){ref-type="fig"}) between 6-month survivors (mean 7.2 ± 4.8%) versus non-survivors (mean 7.3 ± 1.7%). Similarly, we did not observe significant differences in baseline percent positive IFN-γ+ cells ([Fig 4D--4F](#pone.0224775.g004){ref-type="fig"}) with a mean 5.3 ± 5.1% among 6-month survivors versus 19.8 ± 20.5% among non-survivors (P \> 0.05).

![Expression of Granzyme B and IFN-γ in isolated peripheral blood mononuclear cells.\
PBMCs were isolated from dog patients on trial and analyzed via flow cytometry for the expression of activation markers. Baseline PBMC expression between dogs who were alive at 6 months versus those who died showed no significant difference in percent granzyme B positive (A) or percent IFN-γ positive PBMCs (D). Representative flow cytometry staining for granzyme B (B) with FMO control (C) and IFN-γ (E) with FMO control (F) is shown.](pone.0224775.g004){#pone.0224775.g004}

Intra-tumoral immune phenotype {#sec016}
------------------------------

As shown in [Fig 5](#pone.0224775.g005){ref-type="fig"}, we next evaluated the tumor microenvironment (TME) of OSA in both untreated dogs and study subjects using immunohistochemistry and qRT-PCR. Lymph node tissue from a non-tumor bearing dog (Golden Retriever) and tumor tissue from two soft tissue sarcoma and three OSA patients (all untreated and not study patients) were evaluated for baseline lymphocyte infiltration ([Fig 5A](#pone.0224775.g005){ref-type="fig"}). Immunohistochemical analysis of these tumors revealed minimal CD3 infiltration in untreated tumors compared to CD3-rich normal lymph node as a positive control. PCR analysis of PBMCs ([Fig 5A](#pone.0224775.g005){ref-type="fig"}) from these same tumor-bearing, but non-study patients showed a statistically greater expression of circulating CD3 transcripts compared to CD8 and NKG2D, and the expression of these transcripts in PBMCs was approximately 100-fold greater than the respective expression in OSA tumor tissue (P \< 0.0001). In addition, within OSA tumor tissue ([Fig 5A](#pone.0224775.g005){ref-type="fig"}), the expression of the predominantly NK transcript NKG2D was significantly lower than the expression of both CD3 and CD8 (P \< 0.05).

![Intra-Tumoral immune cell infiltration and gene expression in dog sarcomas.\
(A) Lymph node from a dog necropsy specimen was compared to tissue from untreated dog soft tissue sarcoma and osteosarcoma cases. Immunohistochemical staining for CD3+ cells revealed high infiltration in normal lymph node (left) versus rare to absent lymphocyte presence in soft tissue sarcoma (middle) or osteosarcoma (right) tumors. Scale bar = 200 μm. RNA analysis by PCR of PBMCs from healthy dogs (A--bottom left) demonstrated greatest expression of CD3 compared to CD8 or NK marker NKG2D. Expression of these genes in PBMCs was approximately 100-fold greater than expression in osteosarcoma tumor tissue (A--bottom right), and intra-tumoral expression of NKG2D was significantly lower than both CD3 and CD8. Technical replicates from one of 3 experiments are shown. \* P\<0.05, \*\*\* P\<0.001 via one-way ANOVA with Tukey's post-test. (B) Tumor tissue from 8 study subjects was obtained at baseline and after palliative RT and intra-tumoral NK and analyzed for change in intra-tumoral gene expression after therapy. qPCR results demonstrated marked heterogeneity in changes in gene expression of key immune-related genes. Interestingly, the patient who lived the longest (17.9 months) showed the greatest fold-change in the expression of CD3, CD8, and IDO1 genes. On univariate analysis, there was no significant difference (P\>0.05) in intra-tumoral changes in gene expression and survival for CD3 (C), CD8 (D), IDO1 (E), IL-10 (F), IL-6 (G), or TGF-β (H). Symbols represent fold change in gene expression from before therapy to after using pairwise comparisons from individual treated dogs. Mean fold change with standard deviation is shown. Groups were compared using an unpaired t-test.](pone.0224775.g005){#pone.0224775.g005}

We then evaluated the expression of immune-related genes in matched biopsy specimens from eight study dogs where pre- and post-treatment tumor tissue was available before and after palliative RT and intra-tumoral NK. As shown in [Fig 5B](#pone.0224775.g005){ref-type="fig"}, there was marked heterogeneity in the expression of immune-related genes after RT plus NK transfer, both within and among patients. For example, two patients (patient 1 and patient 8) showed notable increases in the expression of CD3 and CD8, while two different patients showed greater than 10-fold increases in IL-6 expression. Patient 8 also showed an approximately 40-fold increase in the expression of IDO1 ([Fig 5B](#pone.0224775.g005){ref-type="fig"}). We then assessed whether there was any correlation between the changes in gene expression of these immune genes and patient survival. As shown in [Fig 5C--5H](#pone.0224775.g005){ref-type="fig"}, we observed no statistically significant differences in changes in expression of genes of interest and survival. Similar to the levels of circulating IL-6, we did observe that study dogs who died within 6 months appeared to have numerically greater (but not statistically different) increases in intra-tumoral expression of IL-6 ([Fig 5G](#pone.0224775.g005){ref-type="fig"}), although the two patients with elevated levels may represent outliers in an otherwise small sample size. However, despite the lack of significant differences between survivors and non-survivors, these data reinforce the validity of using these endpoints as hypothesis-generating data for evaluation in future immunotherapy trials.

The cancer genome atlas {#sec017}
-----------------------

Recent high impact publications using TCGA data have characterized the breadth and depth of genetic and epigenetic abnormalities in multiple human cancers, including sarcomas. Studies of TCGA data have also demonstrated the immune landscape of human malignancy with provocative prognostic implications \[[@pone.0224775.ref019]--[@pone.0224775.ref021]\]. With these results in mind, we sought to analyze TCGA data from human STS (as data on human OSA are not available) looking for differences in the expression of intra-tumoral immune genes of interest and their relationship with survival ([Fig 6](#pone.0224775.g006){ref-type="fig"}). In particular, we focused on genes associated with cytotoxic lymphocyte phenotype and function (CD3, CD8, Interferon-γ, Granzyme B, Perforin, and IL-2 receptor B/CD122) as well as IL-6 and IL-6 receptor given our serum ELISA and tumor PCR results for IL-6 (Figs [3](#pone.0224775.g003){ref-type="fig"} and [5](#pone.0224775.g005){ref-type="fig"}). In order to identify potentially meaningful differences in the prognostic effect of these genes of interest, we categorized gene expression levels based on high expression (quartile 4) and low expression (quartile 1).

![Intra-tumoral gene expression and survival outcomes in human sarcomas from the cancer genome atlas.\
The Cancer Genome Atlas (TCGA) was queried for gene expression data with immunoregulatory function from human sarcoma patients with non-metastatic disease. Patients were categorized into high and low expression by quartiles, and survival differences were analyzed between low expression (quartile 1) and high expression (quartile 4). Significant survival differences were identified between high and low gene expression for (A) CD3e, (B) CD8a, (C) IFN-γ (E) PRF1 (perforin), (F) CD122/ interleukin 2 (and interleukin 15) receptor subunit beta, (G) IL-6, and (H) IL-6R. Notably, and somewhat paradoxically, greater intra-tumoral expression of IL-6 and IL-6R were associated with superior survival in human sarcomas. Sarcoma patients with higher intra-tumoral GZMB (granzyme B) expression (D) had longer survival, but this difference was not statistically significant (HR 0.65, 95% CI 0.37--1.13, P = 0.13).](pone.0224775.g006){#pone.0224775.g006}

As shown in [Fig 6](#pone.0224775.g006){ref-type="fig"}, we then analyzed survival differences. Notably, we observed that elevated expression in the highest quartile of CD3e (HR 0.51, 95% CI 0.29--0.91, P = 0.02), CD8a (HR 0.45, 95% CI 0.25--0.80, P = 0.006), IFN-γ (HR 0.50, 95% CI 0.28--0.89, P = 0.02), and perforin (PRF1, HR 0.42, 95% CI 0.22--0.80, P = 0.006) in human sarcomas were associated with greater OS. In contrast, although there was a trend for improved survival with greater expression of granzyme B (GZMB) and therefore a lower risk of death with a HR of 0.65, this survival difference was not significantly different (P = 0.13). Interestingly, and somewhat paradoxically given our serum ELISA and tumor tissue PCR results, we observed that higher expression of IL-6 (HR 0.46, 95% CI 0.26--0.82, P = 0.007) and the IL-6 receptor/CD126 (HR 0.46, 95% CI 0.27--0.79, P = 0.004) were both associated with greater OS in human sarcomas ([Fig 6G and 6H](#pone.0224775.g006){ref-type="fig"}).

Discussion {#sec018}
==========

Immunotherapy is rapidly becoming the 4^th^ arm of cancer therapy. Breakthrough advances using inhibitors of PD-1, PD-L1, and CTLA-4 and chimeric antigen receptor (CAR) T cells have clearly identified immunotherapy as the future of clinical oncology. However, despite these exciting advances, more basic and translational research is needed to extend the promise of cancer immunotherapy to greater numbers of patients since significant subsets of patients either do not respond to treatment or develop resistance \[[@pone.0224775.ref022]\]. A key step in advancing cancer immunotherapy will be the identification of more robust biomarkers of response and resistance \[[@pone.0224775.ref023]\], and studies in dogs with spontaneous cancers are ideal for this purpose as dogs represent an important link in translating immunotherapy from pre-clinical mouse studies to clinical trials in humans \[[@pone.0224775.ref011]\].

Dogs with spontaneous tumors have a number of advantages over mice as therapeutic models, including extensive homology between canine and human genomes, comparable genetic complexity and tumor heterogeneity, and similar host-tumor interactions in the TME. Therefore, dog clinical trials are an important mechanism to evaluate novel immunotherapy approaches, especially for NK cellular therapy which has proven challenging to effectively implement in human solid tumors \[[@pone.0224775.ref024]\]. We have previously reported the feasibility of our first-in-dog clinical trial of intra-tumoral NK in dogs with OSA \[[@pone.0224775.ref013]\]. In this follow up analysis, we describe the utility of monitoring serum and tumor biomarkers and their correlations with outcome.

Though limited in patient number, our results suggest that there may be a predictive role for pre-treatment serum cytokines and intra-tumoral gene expression. Specifically, this appears most prominent for pre-treatment serum IL-6, in which low expression may correlate with improved survival and/or response to therapy. This correlation with IL-6 is consistent with a large body of literature from human studies suggesting that IL-6 adversely impacts cancer extent of disease and prognosis \[[@pone.0224775.ref025]\]. Interestingly, however, analysis of TCGA data suggests that IL-6 and IL-6R expression in the sarcoma TME may favorably impact OS, though we are unable to differentiate soluble IL-6R on our analysis, which may result in these somewhat paradoxical effects While our study does not answer these critical questions regarding which immune genes and signatures reliably predict prognosis and response to therapy, it does lends support to the validity of using the canine model for more detailed immune dissection. As individual biomarkers often have limited predictive value in larger data sets given the heterogeneity of human and dog patients, immune signatures and gene clusters may prove to be more robust prognostic and predictive tools, as was suggested by a recent multispecies analysis by Scott et al \[[@pone.0224775.ref026]\].

The search for putative prognostic or predictive biomarkers has been intensely investigated in cancer therapy, particularly immunotherapy, where only a subset of patients will respond to treatment. Currently, the most useful immune biomarkers for efficacy of immunotherapy have been intra-tumoral PD-L1 expression, magnitude of tumor mutational burden \[[@pone.0224775.ref027],[@pone.0224775.ref028]\], as well as the quantity of tumor infiltrating lymphocytes (TILs) pre- and post-therapy \[[@pone.0224775.ref029],[@pone.0224775.ref030]\]. These biomarkers are the subject of much investigation in human trials for their ability to predict response to immunotherapy. Although no such correlation has yet been made in the canine population, PD-L1 expression and tumor mutation burden are unlikely to be related to outcome or response to therapy in non-T-cell based therapies such as NK cellular therapy. Of note, our limited data do suggest that dog OSA has relatively limited T cell infiltration at baseline consistent with immunologically "cold" tumors and that intra-tumoral NK transfer can stimulate infiltration of cytotoxic T lymphocytes \[[@pone.0224775.ref031]\]. Although additional studies are needed to validate TILs as a prognostic biomarker in dog OSA, our data demonstrate that both IHC and PCR can reliably detect these markers in future studies \[[@pone.0224775.ref032]\]. Similarly, although studies have identified robust immune infiltrates in dog OSA by next-generation sequencing, the number of immune cells detectable by IHC is low \[[@pone.0224775.ref026],[@pone.0224775.ref033]\].

The intra-tumoral immune phenotype also provides important insight into the TME and illustrates the correlation between peripheral and intra-tumoral expression. Our data highlight the difference between the peripheral and intra-tumoral T cell subpopulations, lending further evidence to the growing body of research on the critical role of TILs in diverse cancer types \[[@pone.0224775.ref034]--[@pone.0224775.ref038]\]. Analysis of untreated tumors in our study highlight the relative paucity of immune infiltration within canine sarcomas, and it is this lack of immune infiltration that promotes the rationale for immunomodulatory RT with NK adoptive transfer to increase immune infiltration. The canine patients in this study recapitulate the human finding that subsets of intra-tumoral immune infiltrates differ from the proportions found in peripheral blood. More so, changes in these subpopulations indicate that immunotherapy can transform a lymphocyte negative ("cold") tumor to a lymphocyte positive ("hot") tumor. This is particularly relevant in the context of tumor MHC-I expression where MHC-I+ tumor cells elicit greater antigen-specific CD8+ T cell responses and MHC-I loss is a well-established mechanism of tumor immune evasion \[[@pone.0224775.ref039]\]. Our study did not address tumor MHC-I expression, but prior research has shown loss of MHC-I in human sarcomas \[[@pone.0224775.ref040]\]. Although this study utilized a single RT regimen consisting of 4 fractions of 9 Gy weekly, evidence suggests that different regimens can alter the immunomodulation elicited. \[[@pone.0224775.ref041],[@pone.0224775.ref042]\]. Further studies moving forward could utilize increased radiation dose and decreased fractionation in an attempt to better augment immune infiltration.

Our study is primarily limited by the small number of patients in our trial. However, although limited in number, the rich immunologic and biochemical data generated provides evidence that immune readouts hold promise as potential biomarkers that can be further studied in follow up dog NK trials and validated for use in human NK clinical trials. Future canine immunotherapy trials should incorporate this level of biochemical and tumor monitoring to aid in identifying novel biomarkers with the goal of improving care across species.

Conclusion {#sec019}
==========

Follow up blood and tissue specimen analysis from our first-in-dog clinical trial of RT and ex vivo expanded autologous NK cell immunotherapy illustrates the feasibility and applicability of utilizing companion dogs for novel cancer therapies. Similar to human studies, analysis of immune markers from canine serum, PBMCs, and tumor tissue is possible and provides valuable immune monitoring data for biomarker analysis. These results reinforce the value of canine immunotherapy trials to speed translation of novel immunotherapy approaches with particular emphasis on identifying novel predictive and prognostic biomarkers that may be beneficial to both dog and human patients.
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Dear Dr. Gangopadhyay and PLOS ONE reviewers,

Thank you for your comprehensive review of our manuscript. We appreciate the editor's and reviewer's comments, and we have attempted to address these comments with a revised version of our manuscript. We hope that you will now consider our manuscript suitable for publication. Please see the following point-by-point responses to the individual comments of the editor and reviewers.

Comments to the Editor

Could you please explain if any form of allogeneic transplantation influences experimental outcomes?

This is an important question as allogeneic immune interactions can have significant effects on the outcomes of cellular therapies both in terms of anti-tumor effects as well as toxicities. In human clinical trials, a strong trend in the field is to pursue allogeneic NK transfer as graft-versus-host disease has not been associated with pure NK cell populations (GVHD is primarily mediated by T cells and significant pre-clinical evidence implicates a protective effect of NK cells in GVHD), while allogeneic NK cells have been associated with improved anti-tumor effects (so-called graft-versus-tumor \[GVT\] or graft-versus-leukemia \[GVL\]) in human studies. In our study, since it was a first-in-dog clinical trial and since dog NK cells are not as well characterized as human or mouse NK cells, we intentionally decided to use autologous canine NK cells as an extra precaution to mitigate toxicity given the potential for unexpected toxicities to occur in clinical trials (e.g., if our NK product was not as T-cell depleted as our background data suggested). Therefore, in the dog clinical trial patients we are reporting in this study, we can conclude that there is no effect of allogeneic interactions on the results. However, given that our data suggest that NK transfer in dogs appears to be safe (based on the data available to date) and given our ongoing studies improving the characterization of dog NK cells, we are pursuing allogeneic NK transfer in our follow-up studies since it is reasonable to hypothesize superior anti-tumor effects in these cases. However, key questions will be how allogeneic NK transfer impacts engraftment, activation status, longevity on the transferred NK cells (as well as how much conditioning is necessary to prevent rejection by the host's immune cells). These are all important comments which relate to the editor's question, and we intend to address them in follow-up studies.

A final point is that our current technique to expand and activate autologous canine NK cells is completed through co-culture with a human (and xenogeneic) K562.Cl9 cell line that has been engineered to expressed human membrane bound IL-21 and 4-1BB ligand. This cell line has been well validated for the expansion of human (and now canine) NK cells and undergoes irradiation prior to culturing to prevent expansion and engraftment following adoptive cell transfer. As human and canine NK cells respond similarly to the transfected K562.Cl9 feeder cell line, there does not appear to be any demonstrable xenogeneic effects identified in the canine NK cells as compared to human NK cells. These points have been expanded in the methods section where we describe the clinical trial (page 4) as well as the discussion section, and we thank the editor for this question.

Comments to the Author

5\. Review Comments to the Author

Limitation of the study design. The weekly 9 Gy x 4 fraction regimen may not be ideal for an immunogenic activation. Please discuss how the next studies would be done so as to harness the power of immunogenic RT fractionation and dose.

We appreciate the reviewer's comment and attention to our study design. This is an important area of investigation in the intersecting fields of radiotherapy and immunotherapy. The immunomodulatory effects of radiotherapy, particularly local immune effects on the tumor microenvironment, have been established in preclinical models and include induction of immunogenic cell death, release of antigens for T cell priming, increased T cell homing to tumor sites, shift in the polarization of tumor associated macrophages, and reduction of immunosuppressive stromal cells in the tumor microenvironment, among others. However, radiotherapy can also augment immunosuppressive pathways, including induction of TGF-B and PD-L1, among others. More recent studies in humans suggest that hypo-fractionated radiation schedules produce very different biologic effects than traditional conventionally fractionated radiation, and few studies have addressed these variables in dogs undergoing RT. Especially in dogs, limited preclinical or clinical data are available to guide the selection of radiation dose, fractionation and site in order to optimally synergize with immunotherapy. Therefore, we completely agree with the reviewer that this is a key question for follow-up studies. Since palliative RT protocols are fairly fixed in clinical medicine (human as well as veterinary), and since studies in dogs with cancer nevertheless maintain a focus on the clinical care of the animals, we do not anticipate that it will be feasible to rigorously vary RT doses and fractionation schedules to comprehensively assess the optimal RT strategy for immunogenic activation (which may nevertheless vary by tumor type and target organ like lungs, liver, or soft tissue (McGee et al., 2018. PMID: 29891204). However, moving forward, we are prospectively collecting immune cells and serum from blood and tumor tissue at multiple time points from dog cancer patients undergoing RT with and without immunotherapy (follow up dog NK clinical trials) to more comprehensively assess the effects of RT on immune phenotype and function as the reviewer suggest. Ultimately, we agree that this will be an important area of research in dogs as it is in humans. However, we also anticipate significant heterogeneity in the immune effects of RT which will vary by irradiated site (e.g. brain and bone are more immunosuppressive micro-environments than the lungs) as well as breed, RT dose, schedule, etc...in which case, this concern may remain an ongoing limitation of radio-immunotherapy studies. These points have been added to our discussion section (page 13-14) and additional references have been added to our discussion section (Ref 44-46: Immunobiology of Radiotherapy: New Paradigms; Unlocking the combination: potential of radiation-induced antitumor responses with immunotherapy; Stereotactic ablative radiotherapy induces systemic difference sin peripheral blood immunophenotype dependent on irradiated site).

Did the OSA tumors express HLA?

Our analysis of the OSA clinical samples did not include expression of canine MHC-I or II, in part because dog leukocyte antigen (DLA) is highly polymorphic (as it is in humans) and also because robust reagents to evaluate DLA phenotype are limited at this time (JL Wagner, 2003. PMID: 12692158). However, we completely agree with the reviewer that this is an important area for future study in dog immunotherapy as these haplotypes have clearly been shown to influence CD8 T cell and NK cell effector function in human immunotherapy studies. As we discuss above in our response to the editor's comment, this is a significant focus of our ongoing investigations into methods to optimize dog NK characterization as well as dog NK adoptive transfer. These points have been added to our discussion section on page 13.

If NKG2D-expressing cells were minimal to absent, please discuss how NK cell therapy would be effective.

We agree with the reviewer that this is an important to emphasize, and these results suggest that strategies to stimulate endogenous anti-tumor immunity from cytotoxic NKG2D-expressing cells like NK cells and bystander T cells may be less likely to succeed. However, we hypothesize that this is where improving NK adoptive transfer techniques could be promising since exogenous delivery of cytotoxic NKG2D-expressing NK and T cells can overcome some of the limitations of "cold" tumor with low baseline immune infiltrate. In our data, the bone and soft tissue sarcoma tumors of untreated dogs showed low expression of NKG2D, in addition to other markers of immune effector cells (CD3, CD8). This highlights the relative paucity of immune cell within canine sarcomas and underlies the rationale for a therapy that induces immunomodulation (RT) and aims to increase infiltration of an effector cell population (NK cells). We have modified the manuscript to clarify these points.

In the TCGA analysis, the authors could examine the expression of soluble IL6R, if possible. Because that might be confounding towards the paradoxical results in TCGA versus canine patients.

We appreciate this additional insight and suggestion from the reviewer, as he or she has identified a notable paradox of our data which also intrigued us. The implication from our primary dog data is that over-expression of IL-6 is a negative prognostic factor in dog osteosarcoma while in the TCGA data overexpression of both IL-6 and the IL-6 receptor was associated with superior survival in soft tissue sarcoma patients. Therefore, we certainly agree that further analysis of these results is warranted to reconcile the differences between dog and human which may be species specific, tumor specific, or related to other factors like immune responses and/or therapy (e.g. use of RT in our dog patients). Unfortunately, the TCGA does not delineate membrane-bound versus soluble IL-6R expression in the dataset, although this clearly would be a relevant area to start to address this paradox. The IL-6R can be produced from an alternative splicing event or via proteolytic cleavage at the protein level. To detect RNA level differences from the TCGA, a unique identifier is needed to detect the soluble form of the transcript, and this is not currently available through the TCGA system. Although IL-6 is considered a proto-typical pro-inflammatory cytokine that directs and amplifies the acute phase response to tissue damage and inflammation, IL-6 is also viewed as an immunosuppressive cytokine because of its association with multiple regulatory or suppressive immune-cell populations, such as myeloid-derived suppressive cells, tolerogenic dendritic cells, and tumor-associated macrophages. Further evidence has been drawn from studies correlating circulating IL-6 levels with poor prognosis of various cancers, especially breast cancer. However, data have also demonstrated a role for IL-6 in boosting T cell trafficking to tumors, where they can become activated and cytotoxic (Romano et al, 1997. PMID: 9075932). These points, including discussion on soluble IL-6R, has been added to our revised manuscript on page 12.
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